Sertraline Pharmacokinetics and Dynamics in Adolescents
Abstract
Objective To determine the pharmacokinetics of sertraline in adolescents and assess its effect on a surrogate marker of serotonin transport. Method Pharmacokinetic parameters of a single 50-mg dose of sertraline were determined in 10 adolescents. Steady-state withdrawal kinetics were determined in 12 adolescents taking 50 mg/day and in 6 adolescents taking 100 to 150 mg/day. Platelet serotonin reuptake was measured before and after 2 weeks of daily 50-mg dosing. Results The mean steady-state half-life of 50 mg was significantly shorter (15.3 +/- 3.5 hours) than the single-dose half-life (26.7 +/- 5.2 hours; t = 6.4, p Conclusions The half-life of sertraline 50 mg becomes significantly shorter from the initial dose to steady-state, and many adolescents may benefit from twice-per-day dosing. The steady-state half-life increases as the dose increases. The moderate levels of platelet reuptake inhibition at 50 mg/day indicate that most adolescents may need sertraline doses higher than 50 mg/day to attain a therapeutic response.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Sertraline may require twice daily dosing for optimal use at lower doses, which can adversely affect treatment adherence and complicate prescribing by pediatricians who are new to prescribing psychotropics.
“In addition, like escitalopram, sertraline may require twice daily dosing for optimal use at lower doses [170], which can adversely affect treatment adherence and complicate prescribing by pediatricians who are new to prescribing psychotropics.”
From A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders (2021) · cites this paper as [170]
Cites
KELLER, M. B., RYAN, N. D., STROBER, M., KLEIN, R. G., KUTCHER, S. P., BIRMAHER, B., HAGINO, O. R., KOPLEWICZ, H., CARLSON, G. A., CLARKE, G. N., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107000-00010 · Cited by 641 · see citing works
Self-citationFluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Birmaher, B., & Brent, D. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318145ae1c · Cited by 1,056 · see citing works
Self-citationWalter, H. J., Bukstein, O. G., Abright, A. R., Keable, H., Ramtekkar, U., Ripperger-Suhler, J., & Rockhill, C. (2020) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2020.05.005 · Cited by 335 · see citing works
The pharmacological management of depression
Kupfer, D. J. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/dkupfer · Cited by 69 · see citing works
Rohden, A. I., Benchaya, M. C., Camargo, R. S., Moreira, T. D. C., Barros, H. M. T., & Ferigolo, M. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.017 · Cited by 35 · see citing works
Peterson, B. S., West, A. E., Weisz, J. R., Mack, W. J., Kipke, M. D., Findling, R. L., Mittman, B. S., Bansal, R., Piantadosi, S., Takata, G., et al. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03314-y · Cited by 13 · see citing works
- Authors
- AXELSON, D. A., PEREL, J. M., BIRMAHER, B., RUDOLPH, G. R., NUSS, S., BRIDGE, J., & BRENT, D. A.
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 41
- Issue
- 9
- Pages
- 1037-1044
- ISSN
- 0890-8567
- Cited by
- 61
- References
- 2
- Language
- en
- Funders
- NIMH (grants MH-18591 and MH-55123 (PI: Dr. Brent), MH-70008 (PI: Dr. Birmaher), MH-30915 (Core PI: Dr. Perel), and MH-01878 (PI: Dr. Axelson))
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
